{"title":"Effect of maternal beta-blocker treatment on mean fetal heart rate","authors":"Sarah Hautier MD , Thi Minh Thu Nguyen MD , Arane Kim MD , Tiphaine Barral MD , Dominique Luton PhD","doi":"10.1016/j.xagr.2024.100423","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>During pregnancy, the prescription of beta-blockers to the mother may be necessary for pre-existing chronic conditions. Their use raises concerns due to potential effects on the fetus.</div></div><div><h3>Objectives</h3><div>This study aimed to investigate the impact of beta-blockers on mean fetal heart rate in pregnant women treated with these medications compared to an untreated patient group.</div></div><div><h3>Study Design</h3><div>This was a retrospective case-control study involving 90 patients, divided into two groups: 45 patients on beta-blockers and 45 untreated patients. Included patients delivered singleton pregnancies after 24 weeks of gestational age at two university hospitals in Île-de-France between 2009 and 2021. They were matched based on age, parity, and gestational age at delivery. Fetal heart rate and maternal heart rate were recorded on the day of delivery. Pregnancy outcomes were studied secondarily.</div></div><div><h3>Results</h3><div>There was no significant difference in mean fetal heart rate between the two groups: 87% of fetuses from mothers treated with beta-blockers had a heart rate between 110 and 150 bpm, compared to 93% of fetuses in the second group (<em>P</em>=.71). Among patients taking beta-blockers, the most commonly used treatment was bisoprolol.</div></div><div><h3>Conclusion</h3><div>The study did not reveal a significant effect of beta-blockers on fetal heart rate. However, close monitoring and appropriate clinical management are still necessary for pregnant patients on beta-blocker treatment due to other potential implications like intra-uterine growth restriction for both the mother and the fetus.</div></div>","PeriodicalId":72141,"journal":{"name":"AJOG global reports","volume":"5 1","pages":"Article 100423"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699721/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJOG global reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666577824001175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
During pregnancy, the prescription of beta-blockers to the mother may be necessary for pre-existing chronic conditions. Their use raises concerns due to potential effects on the fetus.
Objectives
This study aimed to investigate the impact of beta-blockers on mean fetal heart rate in pregnant women treated with these medications compared to an untreated patient group.
Study Design
This was a retrospective case-control study involving 90 patients, divided into two groups: 45 patients on beta-blockers and 45 untreated patients. Included patients delivered singleton pregnancies after 24 weeks of gestational age at two university hospitals in Île-de-France between 2009 and 2021. They were matched based on age, parity, and gestational age at delivery. Fetal heart rate and maternal heart rate were recorded on the day of delivery. Pregnancy outcomes were studied secondarily.
Results
There was no significant difference in mean fetal heart rate between the two groups: 87% of fetuses from mothers treated with beta-blockers had a heart rate between 110 and 150 bpm, compared to 93% of fetuses in the second group (P=.71). Among patients taking beta-blockers, the most commonly used treatment was bisoprolol.
Conclusion
The study did not reveal a significant effect of beta-blockers on fetal heart rate. However, close monitoring and appropriate clinical management are still necessary for pregnant patients on beta-blocker treatment due to other potential implications like intra-uterine growth restriction for both the mother and the fetus.
AJOG global reportsEndocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Perinatology, Pediatrics and Child Health, Urology